IVONESCIMAB
US stocks: Summit shares drop after US FDA declines to approve lung cancer drugSummit Therapeutics faced a notable decline in share value following the FDA's ruling on ivonescimab, which revealed insufficient overall s...
Why is Summit Therapeutics share price up today by 22%?Summit Therapeutics share price is up today by 22% after biopharma firm announced AstraZeneca would invest $2 billion in it. British drugma...
Bristol Myers agrees up to $11.1 billion deal with BioNTech to shake up cancer immunotherapyThe deal, which includes $3.5 billion in unconditional payments, underpins BioNTech's ambition to continue a costly long-term focus on expe...
China’s biotech is redrawing the global pharma map; what India can learnAmerican biggies are joining hands with Chinese companies. AbbVie signed a deal with Simcere Zaiming for a multiple myeloma treatment. Astr...
You thought only DeepSeek routed American titans? Wait, here's a little-known Chinese biotech company whose lung cancer drug could rattle big pharma; here's all about itChinese biotech company Akeso developed a lung cancer drug Ivonescimab, which outperformed Merck's Keytruda in trials. This breakthrough si...
Load More